{
    "nctId": "NCT00423917",
    "briefTitle": "Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 36,
    "primaryOutcomeMeasure": "Six-month Progression-free Survival (PFS) Rate at 6 Months",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast cancer\n\n  * Metastatic disease\n* Must have received an aromatase inhibitor (e.g., letrozole, anastrozole, or exemestane) in an adjuvant or metastatic setting\n* If tumor is HER2 positive (3+ by immunohistochemistry or amplified by fluorescent in situ hybridization) the patient must have received \u2265 1 prior trastuzumab (Herceptin\u00ae)-containing regimen unless there is a contraindication to trastuzumab\n* Measurable or nonmeasurable disease, including any of the following :\n\n  * Bone metastasis\n  * Pleural/pericardial effusion\n  * Ascites\n  * Inflammatory skin changes\n* No microscopic residual disease only\n* Enrolled on or refused enrollment on clinical trial NCCTG-N0392\n* No evidence of active brain metastasis including leptomeningeal involvement\n\n  * CNS metastasis controlled (i.e., at least 2 months of no symptoms or evidence of progression) by prior surgery and/or raditherapy are allowed\n* Hormone receptor status:\n\n  * Estrogen and/or progesterone receptor-positive tumor\n\nPATIENT CHARACTERISTICS:\n\n* Male or female\n* Female patients must be post-menopausal based on any 1 of the following criteria:\n\n  * Age \u2265 60 years\n  * Age \u2265 45 years with last menstrual period \u2265 12 months prior to study entry\n  * Estradiol and follicle-stimulating hormone levels in postmenopausal range\n  * History of bilateral oophorectomy\n* ECOG performance status 0-2\n* Life expectancy \\> 3 months\n* Fertile patients must use effective contraception during and for 30 days after completion of study treatment\n* WBC \u2265 3,000 mg/dL\n* Hemoglobin \\> 8 g/dL\n* Absolute neutrophil count \\> 1,000/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 2.5 times ULN\n* AST and ALT \u2264 2.5 times ULN\n* Creatinine \u2264 1.5 times ULN\n* Urine protein \\< 1+ OR \\< 1 g of protein by 24-hour urine collection\n\n  * No nephrotic syndrome\n* No uncontrolled hypertension (i.e., blood pressure \\[BP\\] \\> 160/90 mm Hg on \u2265 2 occasions at least 5 minutes apart)\n\n  * Patients who have recently started or adjusted antihypertensive medications are eligible provided BP is \\< 140/90 mm Hg on any new regimen for \u2265 3 different observations in \u2265 14 days\n* No clinically significant cardiac disease, including any of the following:\n\n  * Congestive heart failure\n  * Symptomatic coronary artery disease\n  * Unstable angina\n  * Cardiac arrhythmias not well controlled with medication\n  * Myocardial infarction within the past 12 months\n* No arterial or venous thrombosis within the past 12 months\n* No hemoptysis or gastrointestinal hemorrhage within the past 6 months\n* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 4 weeks\n* No significant traumatic injury within the past 4 weeks\n* No active, unresolved infection\n* No history of hypertensive crisis or hypertensive encephalopathy\n* No history of bleeding diathesis or uncontrolled coagulopathy\n* No history of cerebrovascular accident, hemorrhage, or stroke\n* No allergy or hypersensitivity to drug product excipients, murine antibodies, or agents chemically similar to study drugs\n* No other malignancy within the past 3 years except for basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No other serious medical condition that would preclude study therapy or compliance\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Prior radiotherapy to a target lesion allowed provided there has been clear progression since radiotherapy was completed\n* At least 4 weeks since prior radiotherapy\n\n  * Single-dose radiation for palliation or to a nontarget lesion only allowed within the past 4 weeks\n* No more than 1 prior chemotherapy regimen for metastatic disease\n* No more than 2 prior endocrine (hormonal) therapy regimens in the neoadjuvant, adjuvant, or metastatic setting\n* At least 4 weeks since prior major surgery or open biopsy\n* At least 4 weeks since prior chemotherapy or immunologic therapy\n* At least 2 weeks since prior and no concurrent use of any of the following agents:\n\n  * Aspirin (daily low-dose \\[81 mg\\] aspirin allowed\\])\n  * Thrombolytic agents\n  * Anticoagulants (low-dose anticoagulation therapy to maintain patency of a vascular access device is allowed)\n* No concurrent treatment in another clinical study with investigational procedures or investigational therapies\n* No other concurrent anticancer therapy, including chemotherapy, biologic agents, or radiotherapy\n* No routine use of granulocyte colony-stimulating factors during course 1\n* No concurrent oprelvekin",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}